Gulf Med Pharmacy
Outcome
DEA revoked Gulf Med Pharmacy's DEA registration in December 2021 for repeatedly filling controlled substance prescriptions with unresolved red flags including dangerous drug cocktails, patient travel distances, and above-market cash pricing, while ranking as one of Florida's top-10 oxycodone, hydromorphone, and hydrocodone purchasers.
Details
Gulf Med Pharmacy — Top Florida Opioid Purchaser with Unresolved Red Flags (2017–2021)
Outcome: DEA revoked Gulf Med Pharmacy's DEA registration in a Decision and Order published December 22, 2021, finding that from March 22, 2017, through at least August 8, 2019, the Fort Myers, Florida pharmacy repeatedly ignored obvious red flags of abuse and diversion and filled prescriptions without exercising its corresponding responsibility to ensure legitimacy.
Gulf Med Pharmacy was a small independent pharmacy in Fort Myers, Florida. The DEA's case against the pharmacy established multiple simultaneous categories of diversion indicators. First, the pharmacy was one of the top ten purchasers of oxycodone, hydromorphone, and hydrocodone in the entire state of Florida — an extraordinary purchasing volume for a small independent pharmacy.
The DEA's expert reviewed numerous prescriptions filled by Gulf Med Pharmacy and concluded that the pharmacy regularly dispensed "cocktail medications" — combinations of controlled substances that are widely known to be abused or diverted and that, when taken together, significantly increase a patient's risk of death or overdose — without addressing or resolving this red flag. The pharmacy also served patients who traveled on average 45 miles round trip to obtain their controlled substances, a clear indicator of geographic unusual demand. Further, for controlled substance medications, the pharmacy was charging cash patients over three times the market rate, a significant financial anomaly that indicated the pharmacy was operating as a premium diversion outlet rather than a legitimate healthcare provider.
Each of these indicators — top-10 statewide purchasing volume, systematic cocktail dispensing, 45-mile patient travel, and 3x-market cash pricing — individually constituted an unresolved red flag. Taken together, they represented an unambiguous pattern of serving a drug-seeking customer base rather than providing legitimate pharmacy services. The DEA denied all pending renewal and additional registration applications.
Primary Source: Gulf Med Pharmacy; Decision and Order (Fed. Reg. Dec. 22, 2021)
How Crucible Prevents This
Gulf Med was simultaneously exhibiting multiple quantifiable red flag patterns: top-10 statewide opioid purchasing, cocktail dispensing, patient travel of 45 miles average, and cash pricing at 3x market rate. Any one of these would have been flagged by Crucible's purchasing analytics, cocktail alert controls, geographic outlier detection, and pricing anomaly triggers — together they represent a textbook multi-signal diversion profile that should have been escalated long before DEA intervention.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works